Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...

Evaluating activation of MAPK signaling as a potential mechanism of acquired resistance to lorlatinib in ALK-rearranged lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...

Scientists have discovered that increased expression of a novel long non-coding RNA drives glioblastoma cell growth alongside a genetic amplification found in more than half of glioblastoma tumors, ...

Cullinan Therapeutics, Inc. has a cash-rich balance sheet and no financial debt while trading at a reasonable valuation. Read ...

Cells are enveloped by a lipid membrane that gives them structure and provides a barrier between the cell and its environment. However, evidence has recently emerged suggesting that these membranes do ...

(MEMPHIS, Tenn. – November 6, 2025) The enzyme RNA polymerase II transcribes genes into messenger RNA. This process is guided by modifications to the enzyme’s “tail” called phosphorylation patterns.

CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...